FDA Approves Additional Manufacturing Capacity for Alvotech's Biosimilar Simlandi
Alvotech announced that its biosimilar adalimumab-ryvk, marketed as Simlandi in the U.S., has received FDA approval to expand manufacturing capacity. The approval allows production of the drug substance at a second facility, enhancing supply capabilities for this Humira biosimilar. This development is significant because it supports Alvotech's ability to meet growing demand and potentially increase market share in the competitive biologics space. Biosimilars are critical cost-saving alternatives to brand-name drugs like AbbVie’s (ABBV) Humira, which has faced declining sales due to biosimilar competition. The FDA approval is a regulatory milestone that strengthens Alvotech's position and could lead to improved production efficiency and supply chain resilience.
Topics: biologics license application drug manufacturing pharmaceuticals